Citigroup
LXEO icon

Citigroup’s Lexeo Therapeutics LXEO Stock Holding History

Citigroup’s Portfolio LXEO Stock Details LXEO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$76.5K Sell
13,320
-1,973
-13% -$14K ﹤0.01% 4375
2025
Q4 		$152K Buy
15,293
+7,861
+106% +$71.7K ﹤0.01% 4123
2025
Q3 		$49.3K Sell
7,432
-7,316
-50% -$35.4K ﹤0.01% 4509
2025
Q2 		$59.3K Sell
14,748
-8,579
-37% -$28.2K ﹤0.01% 4670
2025
Q1 		$80.9K Sell
23,327
-1,597
-6% -$7.08K ﹤0.01% 4706
2024
Q4 		$164K Buy
24,924
+1,819
+8% +$14.3K ﹤0.01% 4531
2024
Q3 		$209K Buy
23,105
+11,560
+100% +$138K ﹤0.01% 4315
2024
Q2 		$185K Sell
11,545
-37,632
-77% -$547K ﹤0.01% 3914
2024
Q1 		$771K Sell
49,177
-42,712
-46% -$668K ﹤0.01% 3230
2023
Q4 		$1.23M Buy
+91,889
New +$1.14M ﹤0.01% 2651

Other funds holding LXEO

PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
BlackRock
BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.71B AUM 374.45% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $141B AUM 30.34% 1-Year Est. Return
O
OrbiMed New York $4.59B AUM 125.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return